Premarket Buying Signals for Selling to Medical Device Companies

If you sell to medical device companies, your prospect list probably starts with a clearance. A new 510(k) shows up, a rep adds the company to a sequence, and the first call lands a few weeks later. By then the company has usually chosen the contract manufacturer, test lab, quality system, regulatory consultant, and software it needed to get there.

The work that creates demand in medtech happens before the FDA decision. A team is writing design controls, running verification testing, preparing a submission, and hiring its first quality lead months or years before any clearance is public. That premarket stretch is when many of a device company's first vendor decisions are made.

This guide covers how to find those companies while they are still premarket. It ranks the public records that show premarket activity, gives you working queries for two of them, and explains how to turn a record into an account decision. The method applies whether you sell services, components, software, or capital equipment into the device industry.

Why a Clearance Record Is a Late Signal

Start with what the FDA record can and cannot tell you. A 510(k) is a premarket submission showing that a device is substantially equivalent to a legally marketed device, and a company must submit it at least 90 days before offering the device for sale ^[1]. Premarket approval is the FDA's scientific and regulatory review process for Class III devices ^[2]. The De Novo request is the pathway for novel devices that have no valid predicate ^[3].

All three pathways end in a public decision. None of them begin in public. The openFDA 510(k) endpoint covers clearance records from 1976 to the present and is updated monthly ^[4]. It is a record of decisions. A submission that is still under review does not appear there.

That makes a clearance useful for two things, and neither is "this company is starting a project":

• Commercial launch timing. A company with its first clearance can now sell the device, so sales, service, distribution, and post-market processes become likely next projects. If you sell into that phase, the clearance is on time.
• Pipeline inference. A company that cleared one device in a product family often has the next one in development. The clearance tells you the team, the product code, and the regulatory pathway they know.

If what you sell is bought during development, you need records that appear earlier.

The Premarket Signal Map

A device company leaves public traces long before a decision letter. Each trace maps to a development stage and a likely set of purchases. The table ranks them roughly from earliest to latest.

Two points about this map matter more than any single row.

First, the FDA's own confidentiality rules shape what you can see. Before issuing a marketing authorization, the FDA generally cannot publicly disclose whether a sponsor has requested or received Breakthrough Device designation, unless the sponsor chooses to make that public ^[5]. So the agency is not an early-warning source. The company, its investors, its hiring manager, and its study registrations are.

Second, no single row is a buying signal. A Form D filing tells you a company raised money. A Form D filing plus a first regulatory affairs posting plus a registered feasibility study suggests a company is funded, building a quality function, and generating clinical evidence this year. You act on the combination.

Pull the Records Yourself Before You Buy a List

You can check both of the structured sources with a terminal. Doing this once teaches you what the data looks like and where it is thin, which makes you a better judge of any vendor list built on it.

The ClinicalTrials.gov API returns registered studies as JSON ^[6]. This query asks for industry-sponsored device studies that are recruiting or about to recruit:

curl -s -g "https://clinicaltrials.gov/api/v2/studies?query.term=AREA[InterventionType]DEVICE+AND+AREA[LeadSponsorClass]INDUSTRY&filter.overallStatus=NOT_YET_RECRUITING,RECRUITING&pageSize=50&fields=NCTId,LeadSponsorName,BriefTitle,StartDate"

The `LeadSponsorName` field is your account name. `StartDate` tells you whether the study is ahead of the company or already under way. A not-yet-recruiting status only tells you enrollment has not started. It says nothing about purchasing, so treat it as a reason to ask whether sites and study tools are already chosen. Expect noise: large manufacturers run many post-market studies, so move sponsors that already hold clearances in the same product area to a separate established-manufacturer list.

The openFDA 510(k) endpoint answers the opposite question: who has already been cleared, and in which specialty ^[4]. This query returns cardiovascular clearances decided in a date range:

curl -s -g "https://api.fda.gov/device/510k.json?search=decision_date:[2026-01-01+TO+2026-09-01]+AND+advisory_committee:CV&limit=100"

Use the `applicant` values from this result to split your study sponsors into two lists. A sponsor with no prior clearance in that product area is more likely to be a premarket company. A sponsor that appears many times is an established manufacturer running another program. Keep it, because a new program can still be a valid opportunity, but work it as a different sale with a different buyer.

Turn a Signal Into an Account Decision

A record is an input. The account decision needs three more things: fit, stage, and owner.

Fit. Does this device type need what you sell? Software in a medical device, sterile implants, and reusable capital equipment have different development work and different vendors. Use the product area from the study title, the grant abstract, or a prior clearance's product code to check fit before anything else.

Stage. Place the company on a simple timeline: concept, design and development, verification and validation, submission, launch. Each signal in the table suggests a stage, and two signals narrow it. Write the stage and the evidence link in the account record. A stage without a link is a guess that the next rep will treat as a fact.

Owner. Early device companies are small. The person who owns your problem may be the founder, a VP of R&D, a head of quality and regulatory, or a fractional consultant. Titles are inconsistent. Look for who is named on the grant, who posted the role, and who is listed as the study contact.

Then score the account with a rubric your team can argue about in the open:

The point values are an illustrative starting rubric, not a benchmark. Change the weights after a quarter of results. What matters is that every score has a link behind it, so that a manager can audit why an account was prioritized.

This is the same discipline described in signal-based prospecting: a signal earns outreach only when it is recent, sourced, and tied to a problem you solve. If medtech is new ground for your team, the approach in entering a new vertical without references covers how to build credibility while the list matures.

Write Outreach That Respects What You Do Not Know

Premarket teams are cautious about what they disclose, and they notice when a seller overstates what it knows. A study registration does not tell you their submission date. A job posting does not tell you their quality system is missing. Write to the evidence and ask about the rest.

A workable structure:

1. 1.Name the public fact. "I saw your feasibility study was registered in June."
2. 2.Connect it to a common problem at that stage. "Teams at that point are often deciding how to handle verification testing capacity."
3. 3.Ask a question they can answer in one line. "Is that in-house for you, or are you still choosing a lab?"

Do not guess at their regulatory pathway, timeline, or FDA interactions. Do not reference anything you could only know from a private source. If the reply is "we settled that last year," record it. That answer corrects your stage estimate and tells you which later purchase to come back for.

Timing the second touch matters as much as the first. When a premarket company says "not yet," take the answer at face value. Set the follow-up to the next expected stage change, such as study completion or a new regulatory hire, instead of a fixed fourteen-day cadence.

Keep the List Alive

Premarket lists decay in both directions. Companies advance, stall, get acquired, or shut down. A quarterly pull is too slow for a segment where one funding event changes the whole account.

Set up a light weekly routine:

• Re-run the study and clearance queries and diff the sponsor names against last week's list.
• Check new Form D filings for the industry and states you cover ^[7].
• Review new quality, regulatory, and clinical job postings at accounts already on the list.
• Move any account with a new clearance from the premarket list to the launch list, with a different message and often a different owner.
• Expire any signal older than twelve months unless a newer one supports it.

This is where tooling helps. Greenway's buying signal view tracks account changes such as funding, hiring, and company announcements, and the researched leads workflow attaches the source and the likely owner to each account so a rep starts from evidence. Industry-specific registries like the ones above are worth checking directly as well. Your team still decides which combinations of signals count as a stage change for what you sell.

Frequently Asked Questions

Can I see 510(k) submissions that are still under review?

No. The public 510(k) data is a record of clearance decisions ^[4]. To find companies before a decision, use the earlier traces: funding filings, hiring, grants, and registered studies.

Is a Breakthrough Device designation a reliable early signal?

Only when the company announces it. The FDA generally cannot disclose a designation request or decision before marketing authorization unless the sponsor makes it public ^[5]. When a sponsor does announce one, it confirms active FDA interaction and a device aimed at a serious condition.

How far ahead of clearance do these signals appear?

It varies too much by device type and pathway to give one number. A software device on a 510(k) path and an implant on a PMA path run on very different timelines. Track the interval in your own closed deals: the date of the first signal you could have seen against the date the company bought.

What if the account is a large manufacturer and not a startup?

The same records apply, but the signal means something different. A new study from an established manufacturer points to a specific program and business unit, not a company-wide buying window. Route it to the rep who owns that account and look for the program lead.

Should we buy a medtech intent data feed?

Check what it is built from first. If the feed is mostly clearance records and web traffic, you can reproduce the useful part yourself, and it will still point you at companies after their decision. A feed earns its cost when it combines several early records, dates each one, and links to the source.

Start with One Specialty and Fifty Names

Pick the one device specialty where you already have customers. Pull the registered device studies for it, move sponsors with prior clearances in that specialty to a separate established-manufacturer list, and add funding and hiring evidence for whoever remains. Fifty sourced names with a stage and an owner are a better place to spend a rep's week than a long list of cleared companies, because you have evidence that each of the fifty may still be deciding.

Review the list weekly for a quarter, record which signals preceded real conversations, and adjust the rubric. Use what you learn to decide which records deserve a weekly check and which data sources are worth paying for.

References

[1] U.S. Food and Drug Administration, Premarket Notification 510(k). https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k

[2] U.S. Food and Drug Administration, Premarket Approval (PMA). https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma

[3] U.S. Food and Drug Administration, De Novo Classification Request. https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request

[4] openFDA, Device 510(k) API. https://open.fda.gov/apis/device/510k/

[5] U.S. Food and Drug Administration, Breakthrough Devices Program. https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

[6] ClinicalTrials.gov, API Documentation. https://clinicaltrials.gov/data-api/api

[7] U.S. Securities and Exchange Commission, Form D. https://www.sec.gov/resources-small-businesses/capital-raising-building-blocks/form-d

[8] National Institutes of Health, NIH RePORTER. https://reporter.nih.gov/